Abstract: Compositions and methods comprising osmium are provided. In some embodiments, the osmium compounds comprise a bidentate ligand. In some embodiments, the osmium compounds are used in method for treating cancer.

Abstract: Compositions and methods comprising osmium are provided. In some embodiments, the osmium compounds comprise a bidentate ligand. In some embodiments, the osmium compounds are used in method for treating cancer.

Abstract: Compositions and methods comprising rhenium are provided. In some embodiments, the rhenium compounds comprise a bidentate ligand. In some embodiments, the rhenium compounds are used in method for treating cancer.

Abstract: Compositions and methods comprising osmium are provided. In some embodiments, the osmium compounds comprise a bidentate ligand. In some embodiments, the osmium compounds are used in method for treating cancer.

Abstract: Compositions and methods comprising rhenium are provided. In some embodiments, the rhenium compounds comprise a bidentate ligand. In some embodiments, the rhenium compounds are used in method for treating cancer.

Abstract: Methods, compounds, and compositions for treating a proliferative disorder or other physiological conditions via a dual targeting anticancer therapy are provided. In some embodiments, a dual targeting anticancer therapy may utilize a composition comprising a platinum agent. The platinum agent may comprise a precursor to a therapeutically active platinum compound and at least one precursor to a vitamin E agent. The vitamin E agent may target cancer cells via a different mechanism of action than the therapeutically active platinum compound resulting in a dual targeting anticancer agent. The method of treatment may involve administering to a patient the dual targeting anticancer agent. Following administration, a therapeutically active platinum compound and a vitamin E agent may form at the physiologically relevant site.

Abstract: Methods, compounds, and compositions for treating a proliferative disorder or other physiological conditions via a dual targeting anticancer therapy are provided. In some embodiments, a dual targeting anticancer therapy may utilize a composition comprising a platinum agent. The platinum agent may comprise a precursor to a therapeutically active platinum compound and at least one precursor to a vitamin E agent. The vitamin E agent may target cancer cells via a different mechanism of action than the therapeutically active platinum compound resulting in a dual targeting anticancer agent. The method of treatment may involve administering to a patient the dual targeting anticancer agent. Following administration, a therapeutically active platinum compound and a vitamin E agent may form at the physiologically relevant site.